RTOG

1
WELCOME

• RTOG
• RA Orientation
• Philadelphia

2
RTOG BACKGROUND

• Established in 1968
• Several International facilities participate in
  RTOG trials
• United States Korea
• Canada Saudi Arabia
• France Ireland
• Israel
• Australia
• NCI Funding and Corporate Support

3
RTOG BACKGROUND

• Opened gt400 Protocols
• Enrolled 65,000 patients to its studies
• Published more than 700 papers
• Maintains a roster of 40 active studies
  devoted to the groups primary disease sites

4
RTOG PRIMARY DISEASE SITES

• BRAIN
• Head Neck
• Lung
• Breast

5
RTOG PRIMARY DISEASE SITES

• GYN
• Genitourinary
• Bladder
• Prostate
• Gastrointestinal
• Esophagus
• Rectum
• Anal Canal
• Stomach
• Pancreas
• Sarcoma

6
MISSION

• Improve survival outcome and quality of life of
  adults with
• cancer
• Evaluate new forms of radiotherapy delivery.
• (brachytherapy, 3-dimensional conformal
  radiotherapy,
• intensity modulated radiotherapy)
  (IMRT)
• Test new systemic therapies in conjunction with
  RT
• (chemotherapy, hormonal treatment, biologic
  agents and
• new classes of cytostatic, cytotoxic and
  targeted therapies)
• Employ translational research strategies to
  identify patient
• subgroups at risk for failure with existing
  treatments and
• identify new approaches for these patients

7
RTOG STAFF

• Over 80 RTOG staff members
• Administrative
• Research Associates
• Statisticians
• Quality Assurance
• Protocol Development

8
ACCOMPLISHMENTS
9
CERVIX CANCERRTOG 9001

• RTOG demonstrated that combining chemotherapy
  with pelvic radiation improves the 5 year
  survival rate for women with locally advanced
  cervix cancer from
• 58 to 73.

10
LUNG CANCERRTOG 9410

• RTOG FOUND THAT HEALTHIER PATIENTS WITH
  INOPERABLE NON-SMALL-CELL LUNG CANCER HAD BETTER
  RESULTS IF THEY RECEIVED CHEMOTHERAPY DURING
  RADIOTHERAPY RATHER THAN PRIOR TO RADIOTHERAPY.

11
HEAD AND NECK CANCERSRTOG 9003

• RTOG demonstrated the superiority of concomitant
  boost radiotherapy and hyperfractionated
  radiotherapy for locally advanced squamous-cell
  carcinoma.
• RTOG demonstrated that patients who received
  chemotherapy together with their radiotherapy
  after surgery were far less likely to have a
  recurrence of their cancer.

12
BRAIN CANCERRTOG 9508

• RTOG improved survival more than
• 33
• for patients with a single brain metastasis by
  using whole brain radiotherapy followed by
  stereotactic radiosurgery boost instead of whole
  brain treatment alone.

13
CNS LYMPHOMARTOG 9310

• RTOG improved the median survival for patients
  with non-AIDS-related primary CNS lymphoma from
• 11.6 months to
• 30.4 months
• by giving high dose chemotherapy for 10 weeks
  prior to RT.

14
PROSTATE CANCERRTOG 8531

• 
  
  

• RTOG found that men who continued on hormonal
  therapy for at least five years after their
  treatment for locally advanced prostate cancer,
  lived longer than men who discontinued the
  hormones earlier than the five year time point.
  
  

15

• THANK YOU !